Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises KKR in the acquisition of Hyperion from Sandvik
Mandate

Vinge advises KKR in the acquisition of Hyperion from Sandvik

December 12, 2017 M&A

Vinge is advising the listed US investment fund KKR on its acquisition of Hyperion, a manufacturer of industrial tool components, from Sandvik.

Hyperion has 1400 employees in a number of jurisdictions and about SEK 3.2 billion in turnover. The transaction is expected to close during the first half of 2018 and is subject to customary completion conditions such as merger filing approvals.

Vinge’s team has consisted of Christina Kokko, Kristina Ekberg, Alex Miler, Marith Welin-Berger and Matthias Pannier (M&A/Corporate), Eva Fredriksson, Mathilda Persson (TSA/IT), Tobias Kempas, Ilze Lukins, Sophia Holm (IP), Kristoffer Larson (real estate), Sara Strandberg (employment law) and Johan Cederlund and Hedvig Ekdahl (environmental).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026